Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hansa Chief Commercial Officer Departs the Company | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Hansa Chief Commercial Officer Departs the Company

A search is underway for a new CCO and US President.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Matthew Shaulis, Chief Commercial Officer and US President, Hansa Biopharma AB, has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and CEO. A search is underway for a new CCO and US President.
 
Søren Tulstrup, President and CEO, Hansa Biopharma remarked, “Matt has been a fantastic addition to the Hansa executive team and has made significant contributions across the organization over the past years. I want to thank Matt for his commitment and dedication to advancing key priorities including commercialization efforts in Europe, acceleration of our ConfIdeS US pivotal study, and the initiation of launch planning in the US, and we wish him well in his new endeavor.
 
This news comes a year after Hansa restructured its organization to better align and focus on key clinical development and commercial priorities—including an approximately 20-25% reduction in its workforce.
 
More recently, Hansa appointed Evan Ballantyne as Chief Financial Officer (CFO).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters